المؤلفون: Ujjani C, Mato A, Hill BT, Allan JN, Lansigan E, Jacobs R, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M

المصدر: Blood and Lymphatic Cancer: Targets and Therapy, Vol Volume 10, Pp 1-5 (2020)

مصطلحات موضوعية: cll, ibrutinib, elderly, Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

Relation: https://www.dovepress.com/the-impact-of-age-on-survival-in-cll-patients-receiving-ibrutinib-as-i-peer-reviewed-article-BLCTT; https://doaj.org/toc/1179-9889

URL الوصول: https://doaj.org/article/55e83f385ab34228a9f4be53365dc63d

المؤلفون: Mato, AR, Roeker, LE, Lamanna, N, Allan, JN, Leslie, L, Pagel, JM, Patel, K, Osterborg, A, Wojenski, D, Kamdar, M, Huntington, SF, Davids, MS, Brown, JR, Antic, D, Jacobs, R, Ahn, IE, Pu, J, Isaac, KM, Barr, PM, Ujjani, CS, Geyer, MB, Berman, E, Zelenetz, AD, Malakhov, N, Furman, RR, Koropsak, M, Bailey, N, Hanson, L, Perini, GF, Ma, S, Ryan, CE, Wiestner, A, Portell, CA, Shadman, M, Chong, EA, Brander, DM, Sundaram, S, Seddon, AN, Seymour, E, Patel, M, Martinez-Calle, N, Munir, T, Walewska, R, Broom, A, Walter, H, El-Sharkawi, D, Parry, H, Wilson, MR, Patten, PEM, Hernandez-Rivas, JA, Miras, F, Escalada, NF, Ghione, P, Nabhan, C, Lebowitz, S, Bhavsar, E, Lopez-Jimenez, J, Naya, D, Garcia-Marco, JA, Skanland, SS, Cordoba, R, Eyre, TA

المصدر: Blood. 136(10):1134-1143

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:144766821

المؤلفون: Roeker, LE, Eyre, TA, Thompson, MC, Lamanna, N, Coltoff, AR, Davids, MS, Baker, PO, Leslie, L, Rogers, KA, Allan, JN, Cordoba, R, Lopez-Garcia, A, Antic, D, Pagel, JM, Martinez-Calle, N, Garcia-Moarco, JA, Hernandez-Rivas, JA, Miras, F, Coombs, CC, Osterborg, A, Hansson, L, Seddon, AN, Jimenez, JL, Wilson, MR, El-Sharkawi, D, Wojenski, D, Ma, S, Munir, T, Valenciano, S, Seymour, E, Barr, PM, Pu, JF, Patten, PEM, Perini, GF, Huntington, SF, Parry, H, Sundaram, S, Skarbnik, A, Kamdar, M, Jacobs, R, Walter, H, Walewska, R, Broom, A, Lebowitz, S, Isaac, KM, Portell, CA, Ahn, IE, Ujjani, CS, Shadman, M, Skanland, S, Chong, EA, Mato, AR

المصدر: Blood. 138(18):1768

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:148338793

المؤلفون: Allan, JN, Shanafelt, T, Wiestner, A, Moreno, C, O'Brien, SM, Li, JL, Krigsfeld, G, Dean, JP, Ahn, IE

المصدر: BRITISH JOURNAL OF HAEMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

مصطلحات موضوعية: ibrutinib, TP53 mutation, del(17p), first-line, chronic lymphocytic leukaemia

URL الوصول: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::bd98128c4bf54823a02e4323e5cd84b5
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5181

المؤلفون: Arruga, F, Gizdic, B, Bologna, C, Cignetto, S, Buonincontri, R, Serra, S, Vaisitti, T, Vitale, N, Garaffo, G, Mereu, E, Diop, F, Neri, F, Coscia, M, Allan, Jn, Piva, R, Oliviero, S, Furman, Rr, Rossi, D, Gaidano, G, Deaglio, S

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od_______970::678c35ea9e9f817daf68546bac3c6b81
http://hdl.handle.net/2318/1691085

المؤلفون: Kittai AS; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Allan JN; Weill Cornell Medicine, New York, NY., James D; Polaris Biostatistics Ltd, Edinburgh, United Kingdom., Bridge H; AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom., Miranda M; AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom., Yong ASM; AstraZeneca, Gaithersburg, MD., Fam F; AstraZeneca, Cambridge Biomedical Campus, Cambridge, United Kingdom., Roos J; AstraZeneca, Gaithersburg, MD., Shetty V; AstraZeneca, Gaithersburg, MD., Skarbnik A; Novant Health Cancer Institute, Lymphoma and CLL Program, Charlotte, NC., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

المصدر: Blood advances [Blood Adv] 2024 Jun 11; Vol. 8 (11), pp. 2861-2869.

نوع المنشور: Journal Article; Comparative Study

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Benzamides*/therapeutic use , Benzamides*/administration & dosage , Benzamides*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/administration & dosage , Pyrazines*/administration & dosage , Pyrazines*/therapeutic use , Pyrazines*/adverse effects , Pyrimidines*/therapeutic use , Pyrimidines*/administration & dosage , Pyrimidines*/adverse effects , Pyrazoles*/therapeutic use , Pyrazoles*/administration & dosage , Pyrazoles*/adverse effects , Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Female ; Male ; Aged ; Middle Aged ; Aged, 80 and over ; Treatment Outcome ; Piperidines

المؤلفون: Ghia P; Division of Experimental Oncology Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele Milan Italy., Owen C; Tom Baker Cancer Centre University of Calgary and Alberta Health Services Calgary Alberta Canada., Allan JN; Weill Cornell Medicine New York New York USA., Barrientos JC; Columbia University Division of Hematology/Oncology at Mount Sinai Medical Center Miami Florida USA., Barr PM; Wilmot Cancer Institute University of Rochester Medical Center Rochester New York USA., Shi C; Biostatistics, Everest Clinical Research Owings Mills Maryland USA., Szoke A; AbbVie Inc, North Chicago, Illinois, USA (Pharmacyclics LLC, an AbbVie Company) South San Francisco California USA., Abbazio C; AbbVie Inc, North Chicago, Illinois, USA (Pharmacyclics LLC, an AbbVie Company) South San Francisco California USA., Krigsfeld GS; AbbVie Inc, North Chicago, Illinois, USA (Pharmacyclics LLC, an AbbVie Company) South San Francisco California USA., Burger JA; Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA.

المصدر: HemaSphere [Hemasphere] 2024 May 27; Vol. 8 (5), pp. e74. Date of Electronic Publication: 2024 May 27 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE

المؤلفون: Samples L; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Voutsinas J; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Fakhri B; Division of Hematology and Oncology, University of California, San Francisco, CA., Khajavian S; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Spurgeon S; Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR., Stephens D; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT., Skarbnik A; Novant Health, Charlotte, NC., Mato A; Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Broome C; Division of Hematology and Oncology, Georgetown University, Washington, DC., Gopal A; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Smith S; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Lynch R; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Rainey M; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Kim MS; Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR., Barrett-Campbell O; Hematology/Oncology Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH., Hemond E; Hematology/Oncology Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH., Tsang M; Division of Hematology and Oncology, University of California, San Francisco, CA., Ermann D; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT., Malakhov N; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY., Rao D; Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Shakib-Azar M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Morrigan B; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Chauhan A; Division of Hematology and Oncology, Georgia Cancer Center, Augusta University, Augusta, GA., Plate T; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Gooley T; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Ryan K; AstraZeneca, Gaithersburg, MD., Lansigan F; Hematology/Oncology Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH., Hill B; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Pongas G; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Parikh SA; Department of Hematology, Mayo Clinic, Rochester, MN., Roeker L; Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Allan JN; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY., Cheng R; Division of Cardiology, University of Washington, Seattle, WA., Ujjani C; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA.

المصدر: Blood advances [Blood Adv] 2024 May 14; Vol. 8 (9), pp. 2085-2093.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Adenine*/analogs & derivatives , Adenine*/therapeutic use , Adenine*/adverse effects , Piperidines*/therapeutic use , Hypertension*/drug therapy , Hypertension*/chemically induced , Antihypertensive Agents*/therapeutic use , Antihypertensive Agents*/adverse effects, Humans ; Male ; Female ; Retrospective Studies ; Middle Aged ; Aged ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Pyrimidines/therapeutic use ; Pyrimidines/adverse effects ; Pyrazoles/therapeutic use ; Pyrazoles/adverse effects ; Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors

المؤلفون: Jain N; The University of Texas MD Anderson Cancer Center, Houston, Texas., Croner LJ; AbbVie, North Chicago, Illinois.; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California., Allan JN; Weill Cornell Medicine, New York, New York., Siddiqi T; City of Hope National Medical Center, Duarte, California., Tedeschi A; ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy., Badoux XC; Ministry of Health, Kogarah, New South Wales, Australia., Eckert K; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California., Cheung LWK; AbbVie, North Chicago, Illinois.; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California., Mukherjee A; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California., Dean JP; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California., Szafer-Glusman E; AbbVie, North Chicago, Illinois.; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California., Seymour JF; Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.; Royal Melbourne Hospital, and University of Melbourne, Melbourne, Victoria, Australia.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Feb 01; Vol. 30 (3), pp. 498-505.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Adenine*/analogs & derivatives , Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell*/genetics , Piperidines* , Sulfonamides*, Humans ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Mutation ; Proto-Oncogene Proteins c-bcl-2/genetics ; Recurrence

المؤلفون: Marullo R; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Rutherford SC; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Revuelta MV; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Zamponi N; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Culjkovic-Kraljacic B; Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, University of Montreal, Montreal, Canada., Kotlov N; BostonGene Corporation, Waltham, Massachusetts., Di Siervi N; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Lara-Garcia J; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Allan JN; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Ruan J; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Furman RR; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Chen Z; Division of Biostatistics, Population Health Sciences Department, Weill Cornell Medicine, New York, New York., Shore TB; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Phillips AA; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Mayer S; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Hsu J; New York University Grossman School of Medicine, New York, New York., van Besien K; University Hospitals Seidman Cancer Center, Cleveland, Ohio., Leonard JP; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Borden KLB; Institute for Research in Immunology and Cancer and Department of Pathology and Cell Biology, University of Montreal, Montreal, Canada., Inghirami G; Pathology and Laboratory Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Martin P; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York., Cerchietti L; Division of Hematology and Oncology, Medicine Department, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, New York.

المصدر: Cancer research [Cancer Res] 2024 Jan 02; Vol. 84 (1), pp. 101-117.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, Non-Hodgkin*/drug therapy , Lymphoma, Large B-Cell, Diffuse*/drug therapy, Humans ; Active Transport, Cell Nucleus ; Karyopherins/metabolism ; Cell Line, Tumor ; Hydrazines/pharmacology ; Receptors, Cytoplasmic and Nuclear/genetics ; Receptors, Cytoplasmic and Nuclear/metabolism ; DNA Damage ; RNA, Messenger/genetics ; RNA, Messenger/metabolism